Shows / Lung Cancer Considered
Lung Cancer Considered
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide…
The show, from its episodes
No episode notes yet. Recurring topics, people and starter picks will appear when notes are available.
Typical episode length
39m · median of 425 episodes with a known length
Solo / guest format
Unknown — existing notes name people mentioned, but do not identify hosts or guests.
Recurring topics
No recurring topics established yet.
Recurring people
No recurring people established yet.
Start here
No starter picks yet — no published episodes with audio and a recorded notes hook.
Episodes
Lung Cancer ConsideredSeminal Trial Series: Crizotinib in PROFILE 1001
Seminal Trial Series: Crizotinib in PROFILE 1001 by IASLC


Lung Cancer ConsideredIASLC - Immunotherapy In Driver - Positive NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and two esteemed oncology colleagues discuss an evolving hot topic: the use of immune…
Lung Cancer ConsideredClinical Discussion in the Management of Early-Stage NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion on the management of early-stage disease, with an eye toward applying…
Lung Cancer ConsideredLCC: The Management Of CNS Metastases In Driver Negative NSCLC
Description: Host Dr. Narjust Florez and two esteemed international clinicians discuss the unique characteristics of CNS metastases in patients with non-small…
Lung Cancer ConsideredLung Cancer Considered in Romanian
Continuing our series of podcasts in different world languages, this episode focuses on lung cancer research and treatment in Romanian. Host: Mihaela Aldea, MD…
Lung Cancer ConsideredThe Importance of Waiting for Biomarker Results in NSCLC
Biomarkers are essential in lung cancer treatment, but they remain underutilized. In addition, clinicians and patients have to wait for those results before…
Lung Cancer ConsideredLCC In Italian--First-Line Treatment Options for EGFR Mutant NSCLC
This episode of Lung Cancer Considered discusses first-line treatment options for EGFR mutant NSCLC, in Italian. Guest: Dr. Jessica Menis is a thoracic medical…
Lung Cancer ConsideredFDA Approval Of Tarlartamab
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recently approved bispecific T-cell engager, tarlatamab, for small cell lung…
Lung Cancer ConsideredASCO 2024 Summary Part 2
In episode two summarizing important lung cancer data presented at ASCO 2024, Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu cover the…
Lung Cancer ConsideredIASLC - ASCO 2024 Summary--Part 1
Title: ASCO 2024 Highlights Part 1 - Plenary Description: ASCO 2024 had so much lung cancer data, two podcast episodes are required to cover all the data…
Lung Cancer ConsideredUpdates in CT Screening for Lung Cancer
Host Dr. Stephen Liu moderates a discussion of lung cancer screening using low dose CT scans. Low dose CT scans have been shown to detect lung cancer earlier…
Lung Cancer ConsideredLCC and Smoking Cessation
May 31st is World No Tobacco Day and to observe this, Lung Cancer Considered host Dr. Narjust Florez leads a discussion on smoking cessation and how to honor…

Lung Cancer ConsideredVirtual Tumor Board: PD-L1 Low NSCLC
In this virtual tumor board episode, host Dr. Stephen Liu leads a discussion about the management of metastatic, PD-L1 low NSCLC. Dr. Apar Ganti is a Professor…
Lung Cancer ConsideredWhen two worlds collide: Adenosquamous histology
In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion about adenosquamous cell carcinoma of the lung, from diagnosis…
Lung Cancer ConsideredKRAS in NSCLC: Beyond G12C
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, other than G12C. This form of lung cancer…
Lung Cancer ConsideredFDA Approval: Adjuvant Alectinib for Resected NSCLC
In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon…
Lung Cancer ConsideredIASLC DEI Initiative Global Member Survey
As part of the IASLC’s 2024 DEI Initiative, the association is gathering member insights through an online survey and a series of virtual focus groups designed…
Lung Cancer ConsideredFDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR…
Lung Cancer ConsideredELCC 2024 Highlights
This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Prague. Host Dr. Stephen Liu discusses the important…
Lung Cancer ConsideredEmerging Agents In Small Cell Lung Cancer
Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive-stage disease. Unlike non-small cell lung…
Lung Cancer ConsideredRadiopharmaceuticals and Lung Cancer
This episode of Lung Cancer Considered focuses on radiopharmaceuticals-- a unique class of drugs that may have the most immediate impact in neuroendocrine…
Lung Cancer ConsideredFDA Approval: 1L Amivantamab plus Chemotherapy for EGFR Exon 20 NSCLC
Amivantamab Approved by FDA today, March 1! In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of…
Lung Cancer ConsideredSeminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC
Today’s episode of Lung Cancer Considered is part of our special series on seminal trials in thoracic oncology, focusing on the phase I study of the PD-1…
Lung Cancer ConsideredFrom the Basics to Next Line Therapy: ALK + NSCLC
ALK fusions represent 3-5% of newly diagnosed non-small cell lung cancers but several therapeutic options do exist. Lung Cancer Considered host Dr. Narjust…
Lung Cancer ConsideredBest Practice for RET NSCLC
Lung Cancer Considered Host Dr. Stephen Liu moderates a discussion in this podcast on RET as a therapeutic target. RET fusions are a known actionable…
Lung Cancer ConsideredBiomarkers in Lung Cancer: Barriers to Implementation
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found that one-third of oncologists were unaware of…
Lung Cancer ConsideredLCC in Cantonese Chinese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of…
Lung Cancer ConsideredLCC in Mandarin Chinese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found one-third of oncologists were unaware of…
Lung Cancer ConsideredLCC in French Canadian: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of…
Lung Cancer ConsideredLCC in French: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of…
Lung Cancer ConsideredLCC in Portuguese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of…
Lung Cancer ConsideredLCC in Japanese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of…
Lung Cancer ConsideredLCC in Spanish: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of…
Lung Cancer ConsideredThe IASLC’s 50th Anniversary and New Strategic Plan
2024 is the 50th anniversary of the International Association for the Study of Lung Cancer and as we enter this monumental year for IASLC, we do so under a new…
Lung Cancer ConsideredLCC in Cantonese: Biomarker Testing and EGFR Mutant NSCLC
Host Dr. Sally Lau, Thoracic Medical Oncologist and Assistant Professor at the New York University Perlmutter Cancer Center, leads a discussion, in Cantonese…
Lung Cancer ConsideredMeet the New IASLC Chief Scientific Officer Dr. Jennifer King
Host Dr. Narjust Florez interviews new IASLC Chief Scientific Officer Dr. Jennifer King. In this podcast episode, Dr. King shares her perspective on how she…
Lung Cancer ConsideredLung Cancer in MENA: Clinical and Research Initiatives
Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as well as how…
Lung Cancer ConsideredIASLC - Oligometastatic Lung Cancer Part 2
In Part Two of this Lung Cancer Considered podcast on Oligometastic NSCLC, host Dr. Narjust Florez and guest Dr. Daniel Gomez discuss treatment alternatives…
Lung Cancer ConsideredLung Cancer Considered: A Three-Year Review
Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu host this retrospective look at the podcast, examining how the podcast started, how the…
Lung Cancer ConsideredIASLC Oligometastatic NSCLC
In Part 1 of a two-part podcast on Oligometastatic lung cancer and the treatment alternatives with local therapy, host Dr. Narjust Florez interviews Dr. Fatima…
Lung Cancer ConsideredMaximizing Supportive Care in Lung Cancer
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guests discuss the importance of palliative care and psychological support for patients…
Lung Cancer ConsideredLung Cancer in MENA: Clinical and Research Initiatives
Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as well as how…
Lung Cancer ConsideredIASLC Chronic Toxicity From Targeted Therapy
IASLC Chronic Toxicity From Targeted Therapy by IASLC
Lung Cancer ConsideredLCC in Korean: Managing EGFR+ NSCLC
Lung cancer experts in Korea discuss the unique challenges they face when treating patients with lung cancer with EGFR and non-small cell lung cancer.
Lung Cancer ConsideredNew Options for Initial Treatment of EGFR Mutant NSCLC
In this episode, host Dr. Stephen Liu leads a discussion on the current first-line treatment options for EGFR-mutant non-small cell lung cancer, including how…
Lung Cancer ConsideredResearch from NACLC: Nutrition as Medicine and Lung Cancer Screening
IASLC Lung Cancer Considered host Dr. Narjust Florez interviews two researchers presenting at the North America Conference on Lung Cancer: Dr. Carolyn Presley…
Lung Cancer ConsideredFDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor
Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1…
Lung Cancer ConsideredFDA Approval: Perioperative Pembrolizumab and KEYNOTE 671
Host Dr. Narjust Florez leads a discussion about the data from the KEYNOTE 671 trial, presented at ASCO 2023 and ESMO 2023, that led to the first approval of…
Lung Cancer ConsideredIt's time to talk about sexual health and lung cancer!
Sexual health of patients with lung cancer is poorly understood, highly prevalent, and not frequently discussed. However, sexual concerns are common in people…
Lung Cancer ConsideredVirtual Tumor Board: Neoadjuvant for Stage III NSCLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the role of neoadjuvant therapy for stage III NSCLC using a virtual tumor…
Lung Cancer ConsideredLCC in Dutch: Lung Cancer Care in The Netherlands
This episode of Lung Cancer Considered covers the current treatment and research landscape in The Netherlands. The episode is recorded in Dutch and is hosted…
Lung Cancer ConsideredAEGEAN and Beyond: Perioperative Immunotherapy for NSCLC
Lung Cancer Considered host Dr. Narjust Florez leads an informed discussion on the AEGEAN Trial, which explored neoadjuvant durvalumab plus chemotherapy…
Lung Cancer ConsideredUpdated IASLC - Hindi
Title: Lung Cancer Care in India: Approaching a Lung Cancer Diagnosis (Hindi language podcast) The podcast is recorded in Hindi and covers a range of crucial…
Lung Cancer ConsideredFDA Approval: Encorafenib + Binimetinib in BRAF V600E NSCLC
In this podcast, host Dr. Stephen Liu moderates a discussion a recent FDA approval and a specific molecular subtype of NSCLC. On October 11, 2023, the US FDA…
Lung Cancer ConsideredESMO 2023 Highlights: Early Stage NSCLC, SCLC, Thymic Carcinoma
Part 2 of our podcast coverage on ESMO 2023 includes an in-depth interview with Dr. Jarushka Naidoo on early-stage NSCLC, including updates from CheckMate816…
Lung Cancer ConsideredESMO 2023 Highlights: Metastatic NSCLC
In the first part of two podcasts covering recent data presented at the European Society of Medical Oncology Congress 2023, host Dr. Stephen Liu summarizes the…
Lung Cancer ConsideredLung Cancer Care and Research in Japanese
Today’s episode of Lung Cancer Considered is recorded entirely in Japanese and focuses on EGFR mutated lung cancer.